A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the FDA’s crosshairs for the second time in less than a year. | The FDA has ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly ... of select Lilly medicines, including Zepbound, through third-party pharmacy ...

One of them is the pharmaceutical industry. However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Start Your Mornings Smarter!

INDIANAPOLIS — Eli Lilly and Company says it's suing an Indianapolis-based weight loss clinic that it claims is misleading patients about drugs being sold. Lilly claims Premier Weight Loss is selling ...

On Tuesday, Goldman Sachs upgraded shares of Eli Lilly (NYSE:LLY) from Neutral to Buy, while slightly reducing the price target to $888 from $892. The firm's analyst highlighted the pharmaceutical ...

The bottom line: After taking the opportunity to reassess the relative merits of the pipelines of the two firms, we’re raising our fair value estimate for Lilly to $650 per share from $620 and ...